Harrow IP, LLC

47 patents currently held · Updated Nov 14, 2026

3 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jan 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Apr 1 to 29, 2027 · next Apr 1
3 fees due Aug 11 to 20, 2027 · next Aug 11
1 fee due Sep 5, 2027
The maintenance fee for Ocular Lubricant Formulations (US 11,918,603) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
1 fee due Oct 5, 2027
The maintenance fee for Pharmaceutical Formulations of Tranexamic Acid and Their Use (US 9,301,936) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,834,059	Topical Nepafenac Formulations In force Term ends Jan 31, 2027 · High confidence	In force	Term ends Jan 31, 2027	High confidence
US 7,947,295	Ophthalmic Compositions Containing a Synergistic Combination of Two Polymers In force Ends no later than Jun 1, 2027 · Low confidence	In force	Ends no later than Jun 1, 2027	Low confidence
US 8,101,582	Topical Ophthalmic Compositions Containing Tobramycin and Dexamethasone In force Ends no later than Dec 19, 2027 · Medium confidence	In force	Ends no later than Dec 19, 2027	Medium confidence
US 8,450,287	Topical Ophthalmic Compositions Containing Tobramycin and Dexamethasone In force Term ends Dec 19, 2027 · Medium confidence	In force	Term ends Dec 19, 2027	Medium confidence
US 7,795,316	Topical Ophthalmic Compositions Containing Tobramycin and Dexamethasone In force Term ends Aug 3, 2028 · High confidence	In force	Term ends Aug 3, 2028	High confidence
US 7,758,883	Three Layer Artificial Tear Formulation In force Term ends Dec 8, 2028 · High confidence	In force	Term ends Dec 8, 2028	High confidence
US 8,211,880	Low Viscosity, Highly Flocculated Triamcinolone Acetonide Suspensions for Intravitreal Injection In force Term ends Mar 10, 2029 · High confidence	In force	Term ends Mar 10, 2029	High confidence
US 8,128,960	Low Viscosity, Highly Flocculated Triamcinolone Acetonide Suspensions for Intravitreal Injection In force Term ends Dec 17, 2029 · High confidence	In force	Term ends Dec 17, 2029	High confidence
US 9,662,398	Carboxylvinyl Polymer-Containing Nanoparticle Suspensions In force Term ends Dec 1, 2030 · High confidence	In force	Term ends Dec 1, 2030	High confidence
US 8,921,337	Carboxyvinyl Polymer-Containing Nanoparticle Suspensions In force Term ends Mar 31, 2032 · High confidence	In force	Term ends Mar 31, 2032	High confidence

10 of 47 patents shown.

Pro members see all 47.

Pro members: see all 47 patents

Also on record, not counted in the 47: 3 patents in force now held by others · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 4 abandoned · 7 no status recorded

List them